Your browser doesn't support javascript.
loading
Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65.
Xu, JiaLi; Feng, YaDong; Song, GuoXin; Gong, QiXing; Yin, Li; Hu, YingYing; Luo, Dan; Yin, ZhiQiang.
Afiliação
  • Xu J; Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Feng Y; Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Song G; Department of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Gong Q; Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Yin L; Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Hu Y; Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Luo D; Department of Dermatology, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
  • Yin Z; Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Pharmacol ; 9: 67, 2018.
Article em En | MEDLINE | ID: mdl-29520229
Background: Topical calcineurin inhibitors including tacrolimus and pimecrolimus are used in the treatment of many inflammatory skin diseases mainly via blocking T-cell proliferation. Our previous studies found that pimecrolimus 1% cream could reverse high-dose ultraviolet B (UVB) irradiation-induced epidermal Langerhans cell (LC) reduction via inhibition of LC migration. We conducted this study to investigate the effects of topical tacrolimus 0.03% ointment on high-dose UVB-irradiated human epidermal LCs. Methods: Twenty fresh human foreskin tissues were randomly divided into four groups as follows: Control, Tacrolimus (0.03%), UVB (180 mJ/cm2), and UVB (180 mJ/cm2) + Tacrolimus (0.03%). Four time points were set as follows: 0, 18, 24, and 48 h. We collected culture medium and tissues at each time point. The percentage of CD1a+ cells in the medium was detected by means of flow cytometry. Each tissue was prepared for immunohistochemistry, real-time quantitative PCR, and western blot. HaCaT cells were cultured and divided into four groups: Control, Tacrolimus (1 µg/ml), UVB (30 mJ/cm2), and UVB (30 mJ/cm2) + Tacrolimus (1 µg/ml). The cells were incubated for 24 h and prepared for real-time quantitative PCR and western blot. Results: Topical tacrolimus significantly reversed high-dose UVB irradiation-induced epidermal LC reduction and CD1a+ cell increment in culture medium. Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-α (TNF-α) and nuclear factor kappa B (NF-κB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-α expression in cultured tissues. Finally, TNF-α antagonist (recombinant human TNF-α receptor II: IgG Fc fusion protein) could significantly reverse UVB irradiation-induced epidermal LC reduction. Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-α secretion in keratinocytes via regulation of NF-κB/p65.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article